title: Performance of Biopsy Needle With Therapeutic Injection System to Prevent Bleeding Complications.
abstract: Renal disease is epidemic in the United States with approximately 8 × 106people having chronic kidney disease. Renal biopsies are widely used to provide essential diagnostic information to physicians. However, the risk of bleeding complications possibly leading to life-threatening situations results in the contra-indication of biopsy in certain patient populations. Safer renal biopsies will allow more accurate diagnosis and better management of this epidemic health problem. We report the preclinical testing of a novel biopsy device called the therapeutic injection system (TIS). The device introduces a third stage to the standard two-stage side-cut percutaneous biopsy process. The third stage is designed to reduce bleeding complications by injecting a hemostatic plug at the time of biopsy. Laboratory evaluation and preliminary in vivo animal testing using an anticoagulated porcine model of the TIS and Bard Monopty®(Bard Medical, Covington, GA) control device were performed. The hemostatic material Gelfoam®(Pfizer, Brussels, Belgium) was selected as the active material comprising the hemostatic plugs. The performance of two composite plugs, one composed of polyvinyl alcohol (PVA) combined in 2:1 and 12:1 ratios with the hemostatic material, and one plug composed of 100[Formula: see text] hemostatic material were tested. Stroke sequence and hemostatic plug deployment were verified by sequential firing of the TIS biopsy needle into clear gelatin and ex vivo bovine kidney specimens. In vivo trials with porcine specimens revealed a significant reduction in blood loss (8.1 [Formula: see text] 3.9 ml, control versus 1.9 [Formula: see text] 1.6 ml, 12:1 PVA/hemostatic, TIS, [Formula: see text] = 0.01, [Formula: see text] = 6). The 100[Formula: see text] hemostatic plug showed a substantial and immediate reduction in blood loss (9.2 ml, control versus 0.0 ml, TIS, [Formula: see text] = 1). The prototype device was shown to work repeatedly and reliably in laboratory trials. Initial results show promise in this approach to control post biopsy bleeding. This solution maintains the simplicity and directness of the percutaneous approach, while not significantly changing the standard percutaneous biopsy procedure.
authors.affiliation: MC3, Inc., 3526 West Liberty, Suite 100 , Ann Arbor, MI 48103 e-mail:  pwong@MC3corp.com.
authors.forename: Philip
authors.initials: P
authors.lastname: Wong
authors.forename: Kent J
authors.initials: KJ
authors.lastname: Johnson
authors.forename: Roscoe L
authors.initials: RL
authors.lastname: Warner
authors.forename: Scott I
authors.initials: SI
authors.lastname: Merz
authors.forename: Grant H
authors.initials: GH
authors.lastname: Kruger
authors.forename: William F
authors.initials: WF
authors.lastname: Weitzel
keywords: biopsy; bleeding; hemostatic; kidney
references.citation: BMC Nephrol. 2002 Jul 11;3:5
references.pmid: 12113655
references.citation: AJR Am J Roentgenol. 2008 Feb;190(2):413-7
references.pmid: 18212227
references.citation: Radiology. 2000 Jun;215(3):689-93
references.pmid: 10831685
references.citation: Nephrology (Carlton). 2005 Jun;10(3):305-10
references.pmid: 15958047
references.citation: Eur J Clin Invest. 2007 Dec;37(12):954-63
references.pmid: 18036029
references.citation: Med Pediatr Oncol. 2001 Jan;36(1):224-6
references.pmid: 11464890
references.citation: BJU Int. 2003 Jun;91(9):817-20
references.pmid: 12780840
references.citation: AJR Am J Roentgenol. 2003 Jan;180(1):167-72
references.pmid: 12490497
references.citation: J Urol. 2008 Jun;179(6):2248-52; discussion 2253
references.pmid: 18423679
references.citation: Clin Exp Nephrol. 2005 Mar;9(1):40-5
references.pmid: 15830272
references.citation: Kidney Int. 2004 Oct;66(4):1570-7
references.pmid: 15458453